

Adolescents and adults at clinical high-risk for psychosis: age-related differences in attenuated positive symptoms syndrome prevalence and entanglement with basic symptoms

Journal Article**Author(s):**

Gerstenberg, Miriam; Theodoridou, Anastasia; Traber-Walker, Nina; Francini, Maurizia; Wotruba, Diana; Metzler, Sibylle; Müller, Mario; Dvorsky, Diane; Correll, Christoph U.; Walitza, Susanne; Rössler, Wolfgang; Heekeren, Karsten

Publication date:

2016-04

Permanent link:

<https://doi.org/10.3929/ethz-b-000110160>

Rights / license:

[In Copyright - Non-Commercial Use Permitted](#)

Originally published in:

Psychological Medicine 46(5), <https://doi.org/10.1017/S0033291715002627>

Adolescents and adults at clinical high-risk for psychosis: age-related differences in attenuated positive symptoms syndrome prevalence and entanglement with basic symptoms

M. Gerstenberg^{1,2*}, A. Theodoridou^{1,3}, N. Traber-Walker², M. Francini², D. Wotruba^{1,4,5},
S. Metzler^{1,3}, M. Müller^{1,3}, D. Dvorsky^{1,3}, C. U. Correll^{6,7,8,9}, S. Walitza², W. Rössler^{1,5,10} and
K. Heekeren^{1,3}

¹The Zurich Program for Sustainable Development of Mental Health Services (ZInEP), University Hospital of Psychiatry Zurich, Zurich, Switzerland; ²University Clinics for Child and Adolescent Psychiatry Zurich, Zurich, Switzerland; ³Department of Psychiatry, Psychotherapy and Psychosomatics, University Hospital of Psychiatry Zurich, Zurich, Switzerland; ⁴Department of Neuroradiology, University Hospital of Zurich, Zurich, Switzerland; ⁵Collegium Helveticum, A Joint Research Institute, University of Zurich and the Swiss Federal Institute of Technology Zurich, Zurich, Switzerland; ⁶The Zucker Hillside Hospital, Psychiatry Research, North Shore – Long Island Jewish Health System (LIJ), Glen Oaks, NY, USA; ⁷Hofstra North Shore-LIJ School of Medicine, Hempstead, NY, USA; ⁸The Feinstein Institute for Medical Research, Manhasset, NY, USA; ⁹Albert Einstein College of Medicine, Bronx, NY, USA; ¹⁰Laboratory of Neuroscience (LIM 27), Institute of Psychiatry, University of Sao Paulo, Sao Paulo, Brazil

Background. The attenuated positive symptoms syndrome (APSS) is considered an at-risk indicator for psychosis. However, the characteristics and developmental aspects of the combined or enriched risk criteria of APSS and basic symptom (BS) criteria, including self-experienced cognitive disturbances (COGDIS) remain under-researched.

Method. Based on the Structured Interview of Prodromal Syndromes (SIPS), the prevalence of APSS in 13- to 35-year-old individuals seeking help in an early recognition program for schizophrenia and bipolar-spectrum disorders was examined. BS criteria and COGDIS were rated using the Schizophrenia Proneness Instrument for Adults/Children and Youth. Participants meeting APSS criteria were compared with participants meeting only BS criteria across multiple characteristics. Co-occurrence (APSS+/BS+, APSS+/COGDIS+) was compared across 13–17, 18–22 and 23–35 years age groups.

Results. Of 175 individuals (age = 20.6 ± 5.8, female = 38.3%), 94 (53.7%) met APSS criteria. Compared to BS, APSS status was associated with suicidality, higher illness severity, lower functioning, higher SIPS positive, negative, disorganized and general symptoms scores, depression scores and younger age (18.3 ± 5.0 *v.* 23.2 ± 5.6 years, *p* < 0.0001) with age-related differences in the prevalence of APSS (ranging from 80.3% in 13- to 17-year-olds to 33.3% in 23- to 35-year-olds (odds ratio 0.21, 95% confidence interval 0.11–0.37). Within APSS+ individuals, fewer adolescents fulfilled combined risk criteria of APSS+/BS+ or APSS+/COGDIS+ compared to the older age groups.

Conclusions. APSS status was associated with greater suicidality and illness/psychopathology severity in this help-seeking cohort, emphasizing the need for clinical care. The age-related differences in the prevalence of APSS and the increasing proportion of APSS+/COGDIS+ may point to a higher proportion of non-specific/transient, rather than risk-specific attenuated positive symptoms in adolescents.

Received 11 July 2015; Revised 9 November 2015; Accepted 11 November 2015; First published online 16 December 2015

Key words: Adolescents, at-risk for psychosis, attenuated positive symptoms, basic symptoms, cognitive disturbances, psychosis.

Introduction

Since schizophrenia remains one of the most severe mental disorders, efforts at preventing the development of

psychosis are crucial (Correll *et al.* 2010; Fusar-Poli *et al.* 2013). Based on prospective studies in clinical high-risk samples (Fusar-Poli *et al.* 2012; Schultze-Lutter *et al.* 2015), the Attenuated Psychosis Syndrome (APS) was included in DSM-5 as a condition for further study as well as an already codable condition under the ‘Other specified psychosis disorder’ category. However, data for the APS criteria, which define ‘attenuated psychosis’ as subthreshold delusions, hallucinations and

* Address for correspondence: M. Gerstenberg, M.D., University Clinics for Child and Adolescent Psychiatry Zurich, Neumunsterallee 3, CH-8032 Zurich, Switzerland.
(Email: miriam.gerstenberg@kjpzdzh.ch)

disorganized speech/thought (APA, 2013), originate mostly from adult or age-mixed, help-seeking samples. This is problematic because developmental aspects may strongly influence experience and expression of attenuated positive symptoms during adolescence (Schimmelmann *et al.* 2013). Further studies in the general population and across different age groups have been demanded and first findings revealed a prevalence of the research-defined attenuated positive symptoms syndrome (APSS) as high as 7.7% in 11- to 13-year-old school-age children ($n = 212$) (Kelleher *et al.* 2012). Conversely, in a sample aged 16–40 years ($n = 1229$) (Schultze-Lutter *et al.* 2013) only 0.4% met APSS criteria. These data in the general population, albeit collected in different countries by different researchers, suggest the possibility of an age-related decline of the prevalence of APSS in the general population.

In psychiatrically ill adolescents, first studies showed a prevalence of APSS as high as 31.7% in mainly outpatients (Lindgren *et al.* 2014) without predicting the onset of psychoses 1 year later, and a prevalence of 23.6% in inpatients (Gerstenberg *et al.* 2015), further questioning the validity of current high-risk criteria in children and adolescents (Schimmelmann & Schultze-Lutter, 2012; Schimmelmann *et al.* 2013).

In help-seeking individuals at clinical high risk for psychosis, a recent meta-analysis further reported age-related effects regarding the transition to psychosis (Schultze-Lutter *et al.* 2015). Namely, lower transition rates occurred in samples of almost entirely minors compared to mixed samples and adults (Schultze-Lutter *et al.* 2015).

In adults and mixed samples, the additional detection of basic symptom (BS) criteria, particularly of a cluster of subtle cognitive disturbances (COGDIS), may help identify individuals at true risk for psychosis (Ruhrmann *et al.* 2010; Schultze-Lutter *et al.* 2014). Basic symptoms preceded, but also co-occurred with attenuated positive symptoms, and the presence of both, COGDIS and APSS, may increase predictive power for conversion to psychosis (Ruhrmann *et al.* 2010; Schultze-Lutter *et al.* 2014).

Taken together, data about the age-related distribution of APSS within one study population are sparse, and little is known about the combined prevalence of APSS and BS criteria across different age groups. Therefore, in the present study, a broad age range was chosen to allow the investigation of age-specific aspects of help-seeking individuals meeting APSS and/or BS criteria.

We aimed to analyze the age-specific distribution of APSS and BS criteria, especially COGDIS, as well as of their combination. Based on prior literature (Kelleher *et al.* 2012; Schultze-Lutter *et al.* 2013; Lindgren *et al.* 2014), we hypothesized that (1) APSS would be more

frequent in adolescents than in adults, and (2) APSS with co-occurring BS criteria, a likely more specific risk constellation, would conversely be less frequent among youth with APSS than in adults with APSS.

Material and method

Setting and participants

As part of an on-going, longitudinal early recognition project for schizophrenia- and bipolar-spectrum disorders (<http://www.zinep.ch>), individuals were recruited in the Swiss region of Zurich, a 1.4 million people catchment area. The study was approved by the local ethics committee (E63/2009) and complies with the Declaration of Helsinki. Legal guardians of minors and adult participants were asked to give written informed consent, minors to provide written assent. The sample was accrued from April 2010 to July 2012. Potential participants had either learned about the study from a project website, flyers, newspaper advertisements, or were referred by general practitioners, counseling services, psychiatrists, or psychologists. Study design, inclusion, and exclusion criteria were previously described (Metzler *et al.* 2014; Theodoridou *et al.* 2014).

In brief, inclusion criteria for the initial sample were: individuals aged 13–35 years, sufficient German speaking ability, meeting at least one of the following at-risk criteria (1) a risk syndrome as defined by the Structured Interview of Prodromal Syndromes and the corresponding Scale for Prodromal Syndromes (SIPS/SOPS) (McGlashan *et al.* 2010), and/or (2) an at-risk state according to BS criteria [i.e. criteria for cognitive-perceptive symptoms (COPER) and/or cognitive disturbances (COGDIS)] as defined by the Schizophrenia Proneness Instrument (Schultze-Lutter, 2007; Schultze-Lutter & Koch, 2010) and/or (3) a potential risk for bipolar spectrum disorders, as defined by a score of either $\geq 14/32$ hypomanic symptoms as assessed with the Hypomania Checklist (Angst *et al.* 2005), or a score of ≥ 12 on the Hamilton Depression Rating Scale (HAMD, Hamilton, 1960). Exclusion criteria were: (1) estimated premorbid IQ < 80, (2) meeting DSM-IV criteria for current substance dependence, any psychotic disorder confirmed by research diagnostic interviews, and/or a medical condition known to affect the brain, and for the present analysis (3) not fulfilling APSS or BS criteria.

Of 305 recruited participants, 52 (17.0%) withdrew their consent before full baseline assessments, 14 (4.6%) were excluded due to a confirmed diagnosis of schizophrenia or schizoaffective disorder, and 64 (21.0%) did not fulfill APSS and/or BS criteria (Fig. 1). The remaining 175 participants were grouped




Fig. 1. Recruitment, analyzed sample and group composition. APSS, Attenuated positive symptoms syndrome; BS, basic symptom criteria.

into APSS *v.* BS and compared on demographic, diagnostic, symptom, and treatment variables.

Procedures

Demographic, past psychiatric illness and treatment information was obtained from participants and, in case of minors, augmented by information from guardians. DSM-IV Axis I diagnoses were screened with the Mini International Neuropsychiatric Interview (MINI/MINI-KID; Lecrubier *et al.* 1997; Sheehan *et al.* 2010). The presence and severity of positive, negative, disorganized, and general symptoms, including attenuated levels, were assessed with the SIPS and rated using the companion SOPS (McGlashan *et al.* 2010). BS criteria were assessed with the Schizophrenia Proneness Instrument – Adult or Child and Youth version, and risk criteria for COGDIS and COPER were coded (Schultze-Lutter, 2007).

Severity of positive symptoms was assessed using the Positive and Negative Syndrome Scale (PANSS; Kay *et al.* 1987), depressive symptoms with the HAMD (Hamilton, 1960); frequency of lifetime hypomanic symptoms with the Hypomania Checklist, and anxiety with the Beck Anxiety Inventory (BAI; Beck *et al.* 1988). Lifetime suicidality was detected with the MINI/MINI-KID and current suicidality was defined by a score ≥ 2 (0–4) on the HAMD suicidality question. Illness severity was rated using the Clinical Global Impressions – Severity scale (CGI-S; Guy, 1976). The

Global Assessment of Functioning scale (GAF; Hall, 1995) was used to assess current and, highest functioning in the past year, and decline within the past year. IQ was estimated with a word recognition test for adults [Mehrfachwahl-Wortschatz-Intelligenztest (MWT-B; Lehrl *et al.* 1995)] or a test of receptive vocabulary for minors [Peabody Picture Vocabulary Test (PPVT; Dunn *et al.* 1965)]. All semi-structured interviews and cognitive testing were administered by experienced and extensively trained psychologists and psychiatrists.

Statistical analysis

Descriptive statistics were provided for socio-demographic and clinical characteristics. To assess group differences, χ^2 statistics for categorical variables (or Fisher's exact test whenever ≥ 1 cell weights were ≤ 5) were used. Continuous outcomes that were normally distributed were analyzed using *t* tests and analysis of variance. Continuous outcomes that were not normally distributed were analyzed using the non-parametric Mann–Whitney *U* test.

Moreover, ordinal logistic regressions using a proportional odds model were performed to examine the relationship between APSS status and the three age groups (1) adolescents (13–17 years, $n = 66$), (2) young adults (18–22 years, $n = 52$), and (3) adults (23–35 years, $n = 57$). Odds ratio (OR) estimates and their 95% confidence intervals (CIs) were reported. Finally,

associations between APSS status and psychopathology were assessed. Group comparisons were performed using *t* tests for two-group comparisons (APSS *v.* BS). All analyses were conducted using STATA/SE 12 (Stata Statistical Software: Stata/SE *v.* 12.0 for Windows; Stata Corporation, USA); all tests were two-sided.

Results

Age-related aspects of APSS and BS prevalences

Of 175 non-psychotic individuals (age = 20.6 ± 5.8 years, age range = 13–35, female = 38.3%), 94 (53.7%) fulfilled APSS criteria (Table 1). Compared to BS criteria, APSS status was associated with younger age (23.2 ± 5.6 *v.* 18.3 ± 5.0 , $p < 0.0001$).

In ordinal regression models, compared to BS criteria, APSS status was negatively associated with age, with prevalences ranging from 80.3% in adolescents to 33.3% in adults (OR 0.21, 95% CI 0.11–0.37, $p < 0.001$).

Within APSS+ individuals, fewer adolescents fulfilled combined risk criteria of APSS+/BS+ 75.5% compared to the older age groups (APSS+/BS+ in young adults 95.5%, in adults 94.7%) (Table 2, Fig. 2).

Similarly, fewer adolescents fulfilled combined risk criteria of APSS+/COGDIS+ (52.8% *v.* 72.7% in young adults, and 78.9% in adults) (Table 2, Fig. 2). Accordingly, significantly more adolescents meet APSS+/BS– (24.5% *v.* 4.6% in young adults and 5.3% in adults) or APSS+/COGDIS– (47.2% *v.* 27.3% in young adults and 21.1% in adults) criteria (Table 2, Fig. 2). All differences were significant comparing adolescents to young adults ($p < 0.0001$ –0.003), whereas no differences between the two adult groups were found.

APSS *v.* BS: diagnostic and treatment characteristics, illness severity, functioning and suicidality

APSS status was associated with a higher frequency of obsessive compulsive disorder (8.6% *v.* 20.2%, $p = 0.035$) and post-traumatic stress disorder (12.8% *v.* 1.2%, $p = 0.003$) (Table 1). In the adolescent subgroup, conduct disorder was more frequent in the BS group (38.5% *v.* 9.4%, $p = 0.020$) (Supplementary Table S2).

Treatment characteristics did not differ between the groups. However, APSS status was associated with higher CGI-Severity, poorer current GAF, and lifetime suicidality (Table 1). Additionally, a decline of $\geq 30\%$ was more frequent in APSS compared to BS (42.4% *v.* 23.5%, $p = 0.015$) groups. In contrast, current suicidality did not differ between the groups (Table 1).

Psychopathology in APSS *v.* BS groups

In addition to the group-defining SIPS positive scores, the SIPS negative, disorganized and general symptom total scores were significantly higher in the APSS than BS group. Similarly, the PANSS positive, negative and general and depressive sum scores were significantly higher in the APSS *v.* BS group ($p < 0.0001$ –0.015), whereas anxiety sum scores did not differ significantly (Table 3).

Discussion

Assessing the age-specific distribution of APSS and BS we found that (1) APSS status was associated with younger age and an age-related differences in prevalences of APSS, ranging from 80.3% in 13- to 17-year-old adolescents to 33.3% in 23- to 35-year-olds, and (2) in adolescents compared with adults, the proportion of co-occurring APSS and BS or the COGDIS risk criterion alone was lowest, whereas the proportion of APSS without BS or COGDIS was highest.

Comparing our overall APSS prevalence of 53.7% to previous studies, our specific sampling strategy, which involved including also participants reporting BS and/or hypomanic symptoms, requires consideration. In clinical high-risk groups of ‘The European Prediction of Psychosis Study’ (Klosterkötter *et al.* 2005) and the ‘North American Prodrome Longitudinal Study’ (NAPLS; Addington *et al.* 2007) the prevalence of APSS was 81.6%, and 94.3%, respectively, but decreased to 50.4% in NAPLS when considering all help-seeking individuals. Therefore, the APSS prevalence in our sample is intermediate between high prevalences in at-risk samples ascertained in early recognition centers and lower prevalences of 31.7% (Lindgren *et al.* 2014) in unselected adolescent psychiatric outpatients, or 28.3% (Gaudiano & Zimmerman, 2013) in unselected adult psychiatric outpatients.

Finding significantly more frequent APSS status in adolescents than adults, we assessed the co-occurrence of APSS+/BS+ or APSS+/COGDIS+, both proposed as more specific risk constellations for psychosis (Ruhmann *et al.* 2010; Schultze-Lutter *et al.* 2014). Interestingly, our results showed that the ratio of APSS+/COGDIS+ to APSS+/COGDIS– was almost 1:1 (52.8% *v.* 47.2%) in adolescents, whereas in both adult groups, the proportion rose to approximately 3:1 pointing to possibly more non-specific/transient attenuated positive symptoms in adolescents. While we cannot draw further conclusions from our cross-sectional data, this hypothesis is supported by first naturalistic longitudinal studies focusing explicitly on help-seeking adolescents (12–18 years). These studies yielded transition rates of only 7.1–15.6% (Ziermans

Table 1. Baseline demographics, treatment, diagnostic, and functional characteristics

	Total (n = 175)	APSS (n = 94)	BS (n = 81)	p value
Demographics				
Sex, female, n (%)	67 (38.3)	34 (36.2)	33 (40.7)	0.64
Estimated IQ ^a (MWTB/PPVT)	102.8 ± 12.4	102.1 ± 13.4	103.5 ± 11.2	0.47
Age, mean ± s.d.	20.6 ± 5.8	18.3 ± 5.0	23.2 ± 5.6	<0.0001
Diagnoses, n (%)				
Anxiety disorders^b				
Social phobia	37 (21.1)	15 (16.0)	22 (27.2)	0.094
Panic disorder	36 (20.6)	19 (20.2)	17 (21.0)	1.00
General anxiety disorder	29 (16.6)	11 (11.7)	18 (22.2)	0.069
Agoraphobia	21 (12.0)	12 (12.8)	9 (11.1)	0.82
Obsessive-compulsive disorder	26 (14.9)	19 (20.2)	7 (8.6)	0.035
Depressive disorders				
Major depressive disorder	94 (53.7)	63 (67.0)	49 (60.5)	0.43
Dysthymic disorder	18 (10.3)	9 (9.6)	9 (11.1)	0.81
Bipolar spectrum disorder	52 (29.7)	30 (31.9)	22 (27.2)	0.51
Substance use disorders^b				
Other drug abuse	17 (9.7)	9 (9.6)	8 (9.9)	1.00
Alcohol abuse	11 (6.3)	5 (5.3)	6 (7.4)	0.76
Trauma- and stressor-related disorders, PTSD	13 (7.4)	12 (12.8)	1 (1.2)	0.003
Eating disorders				
Anorexia nervosa	3 (1.7)	2 (2.1)	1 (1.2)	1.00
Bulimia nervosa	3 (1.7)	1 (1.1)	2 (2.5)	0.60
Total number of diagnoses				
0–2	92 (52.6)	48 (51.1)	44 (54.3)	0.76
≥3	83 (47.4)	46 (48.9)	37 (45.7)	
Mean number of diagnoses ± s.d.	2.6 ± 1.6	2.7 ± 1.6	2.4 ± 1.6	0.26
Treatment characteristics				
Participants receiving any psychotropic drug, n (%)				
Antipsychotics	34 (19.4)	22 (23.4)	12 (14.8)	0.18
Chlorpromazine-equivalent ^c , mean ± s.d.	32.6 ± 118.0	47.6 ± 152.9	15.1 ± 50.2	0.12
Antidepressants	40 (22.9)	17 (18.1)	23 (28.4)	0.15
Other psychotropic drugs (methylphenidate, antiepileptics)	5 (2.9)	4 (4.3)	1 (1.2)	0.38
Severity of illness				
Severity of illness, CGI scale ^d , mean ± s.d.	4.1 ± 0.9	4.4 ± 0.8	3.7 ± 1.0	<0.0001
Level of functioning				
Current functional level, GAF scale ^e , mean ± s.d.	54.9 ± 13.8	51.5 ± 11.9	58.9 ± 14.9	0.001
Highest GAF of past year ^f , mean ± s.d.	72.7 ± 13.4	72.5 ± 12.7	72.9 ± 14.4	0.80
>30% of GAF decline within the past year ^d , n (%)	58 (33.1)	39 (42.4)	19 (23.5)	0.015
Suicidality				
Lifetime suicidality (MINI), n (%)	87 (49.7)	54 (57.5)	33 (40.7)	0.034
Current suicidality (HAMD) ^g , n (%)	46 (26.3)	30 (32.6)	16 (19.8)	0.084

APSS, Attenuated positive symptoms syndrome; BS, basic symptom criteria; MWTB, Multiple Choice Vocabulary Intelligence Test (Mehrfachwahl-Wortschatz-Intelligenztest); PPVT, Peabody Picture Vocabulary Test; PTSD, post-traumatic stress disorder; CGI, Clinical Global Impression; GAF, Global Assessment of Functioning; MINI, Mini International Neuropsychiatric Interview; HAMD, Hamilton Depression Scale;

Bolded *p* values <0.05, data available for ^a166, ^c173, ^d170, ^e167, ^f168 and ^g172 participants; ^bthe total number of participants in each main diagnostic category can be smaller than the sum of the individual diagnoses due to co-morbidity.

et al. 2011; Welsh & Tiffin, 2014) at 24 months, which are much lower than the 2-year transition rate of 29% in mainly adult samples (Fusar-Poli *et al.* 2012). Notably, the clinical high-risk state in an unselected adolescent sample with first mental health contact

was not predictive for transition to psychosis at 1 year, but for psychiatric hospitalization within a follow-up of up to 8.9 years (Lindgren *et al.* 2014). Our data may also indicate that the risk-orientated approach of combining APSS with COGDIS may account

Table 2. Age-group specific distribution of attenuated positive symptoms syndrome (APSS) and basic symptom criteria (BS)

Prevalence in relation to	Adolescents (<i>n</i> = 66, 13–17 years)		Young adults (<i>n</i> = 52, 18–22 years)		Adults (<i>n</i> = 57, 23–35 years)		Total sample (<i>n</i> = 175, 13–35 years)		<i>p</i> value young adults <i>v.</i> adults
	Participants in this age-group, <i>n</i> (%)	Frequency of APSS (%)	Participants in this age-group, <i>n</i> (%)	Frequency of APSS (%)	Participants in this age-group, <i>n</i> (%)	Frequency of APSS (%)	Participants in this sample, <i>n</i> (%)	Frequency of APSS (%)	
APSS	53 (80.3)	(100)	22 (42.3)	(100)	19 (33.3)	(100)	94 (53.7)	(100)	0.43
APSS+/BS+	40 (60.6)	(75.5)	21 (40.4)	(95.5)	18 (31.6)	(94.7)	79 (45.1)	(84.1)	0.42
APSS+/BS–	13 (19.7)	(24.5)	1 (1.9)	(4.6)	1 (1.8)	(5.3)	15 (8.6)	(16.0)	1.000
APSS +COGDIS+	28 (42.4)	(52.8)	16 (30.8)	(72.7)	15 (26.3)	(78.9)	59 (33.7)	(62.8)	0.52
APSS +COGDIS–	25 (37.9)	(47.2)	6 (11.5)	(27.3)	4 (7.0)	(21.1)	35 (20.0)	(37.2)	0.50

COGDIS, Cognitive disturbances.

Bolded *p* values <0.05.

better for developmental characteristics during adolescence since in our sample the overall prevalence decreased from 80.3% (APSS) to 42.4% (APSS +/COGDIS+). Although the two adult groups still showed lower prevalences of APSS+/COGDIS+, the age-related difference was less pronounced than for the other risk profiles. However, to confirm the greater specificity for true psychosis risk of APSS+/COGDIS+ in adolescents, longitudinal studies in youth are required.

Partly, the high frequency of APSS+/COGDIS– may be related to psychiatric co-morbidities that often emerge during adolescence, complicating diagnostic and treatment approaches of patients with attenuated positive symptoms (Welsh & Tiffin, 2012). Furthermore, in adolescents, it may be particularly difficult to differentiate obsessions and post-traumatic stress-related aberrations in thinking and perceptions from APSS. In this context the utility of the DSM-5 APS diagnosis within the psychosis spectrum may be questioned, especially for 13- to 17-year-olds (Yang *et al.* 2010; Arango, 2011). Subsequently, concerns have been raised about premature labeling, stigma and potentially harming treatment strategies, such as an increased use of antipsychotics in young, treatment-naïve individuals reporting attenuated positive symptoms (Corcoran *et al.* 2010; Arango, 2011; Yung *et al.* 2012; Fusar-Poli *et al.* 2013).

Our frequency of 19.4% of patients receiving antipsychotics at study entry corresponds to the rates reported in the NAPLS 1 (24.3%) and 2 (17.6%) studies (Woods *et al.* 2013). Interestingly, treatment characteristics, explicitly antipsychotic medication use and chlorpromazine equivalents did not differ between APSS and BS groups. Clinical decision-making was independent of research assessment, but even though APSS status was associated with a higher degree of symptomatology and overall impairment compared to BS, use and dosage of antipsychotics was similar in both groups. Likewise, in a sample of non-psychotic adolescent inpatients, there was no significant association between antipsychotic medication and severity of attenuated psychotic symptoms and no difference between antipsychotic prescription in APSS and non-APSS youth (Gerstenberg *et al.* 2015). Thus, it remains to be shown if awareness of APSS or the APS diagnosis itself may result in more frequent antipsychotic prescribing to youth or adults fulfilling these criteria.

Irrespective of age, APSS status was associated with suicidality and more clinical impairment, pointing to the close link between APSS and clinical need. Moreover, this finding raises at least the possibility that one reason for lower APSS status in adulthood, assessed cross-sectionally, could be a result of




Fig. 2. Age-group specific distribution of the risk criteria attenuated positive symptoms syndrome (APSS) and cognitive disturbances (COGDIS). Each column represents the group-specific proportional prevalence of APSS: in adolescents, young adults, adults, and in the total sample. Within APSS+ individuals, the prevalence of the combined risk criteria APSS+/COGDIS+ is represented at the bottom, striped part of the column. To assess group differences, χ^2 statistics for categorical variables were used; significant p values between adolescents (13–17 years) and young adults (18–22 years), *n.s.*, non-significant p values between the two adult groups.

completed suicide in youth, requiring further study. For example, in a longitudinal study of general population adolescents, the risk for suicide attempt was associated with attenuated and/or frank psychotic symptoms. Within 1 year, 34% of the adolescents reported at least one suicide attempt compared to 13% of participants with psychopathology without psychotic symptoms, and 4% in the general population (Kelleher *et al.* 2013). The association of APSS with more clinical and/or functional impairment was also shown in selected at-risk populations, inpatients, outpatients and the general population (Addington & Heinssen, 2012; Kelleher *et al.* 2012; Lindgren *et al.* 2014; Schultze-Lutter *et al.* 2013; Gerstenberg *et al.* 2015). We acknowledge several limitations of this study. Although we recruited a large sample of 13- to 35-year-old individuals with a broad range of symptomatology, sample sizes in the age subgroups were modest, the naturalistic design allowed for psychotropic medication treatment. The cross-sectional data limit further conclusions, especially concerning the predictive value of APSS with or without BS across the different age groups. Furthermore, since help-seeking behavior in adolescents is also influenced by care-

takers, social services and/or general practitioners, we cannot exclude that the sample of adolescents may have differed regarding psychopathology from adults. However, our total sample consisted of self-referrals, out-, and inpatients screened for at-risk criteria. Comparing our APSS prevalence of 80.3% in adolescents to 31.7% APSS in an unselected sample of adolescent psychiatric patients (Lindgren *et al.* 2014), the frequency in our enriched sample still seems reasonable. In conclusion, the possibly transient character of attenuated positive symptoms, especially during adolescence, when APSS might occur in the context of various emerging mental diseases, is underlined by the age-specific differences of the prevalence of APSS in our sample and the proportional decrease of APSS+/COGDIS- in adults. More prospective studies in different age groups and large and clearly defined or generalizable samples followed long enough are required. Such studies might clarify the predictive value of APSS with and without other risk indicators, shed further light on the impact of APSS on suicidality and clinical impairment, and pave the way to identify the individual relevance of APSS and start targeted treatment.

Table 3. Severity of symptom domains assessed with the Structured Interview of Prodromal Syndromes (SIPS) and additional psychopathology scales

	Total sample (n = 175)	APSS (n = 94)	BS (n = 81)	p value
SIPS, symptom domains, mean ± s.d.				
Total positive symptoms score	8.1 ± 4.6	11.0 ± 3.5	4.6 ± 3.2	<0.0001
Total negative symptoms score	12.1 ± 6.1	13.5 ± 6.0	10.6 ± 5.9	0.002
Total disorganized symptoms score	4.6 ± 3.0	5.9 ± 3.1	3.0 ± 2.1	<0.0001
Total general symptom score	8.2 ± 3.7	8.8 ± 3.8	7.4 ± 3.5	0.015
Additional psychopathology scales				
Psychosis, mean ± s.d.				
PANSS positive sum score ^a	13.0 ± 4.4	15.3 ± 4.0	10.4 ± 3.2	<0.0001
PANSS negative sum score ^a	14.4 ± 5.9	16.4 ± 6.1	12.0 ± 4.7	<0.0001
PANSS general sum score ^a	31.6 ± 8.1	35.0 ± 7.5	27.7 ± 7.0	<0.0001
Depression, mean ± s.d.				
HAMD-17 sum score ^b	15.3 ± 7.5	16.6 ± 7.9	13.8 ± 6.7	0.019
Anxiety, mean ± s.d.				
Beck Anxiety Inventory ^c	19.1 ± 11.4	19.4 ± 11.4	18.7 ± 11.4	0.72

APSS, Attenuated positive symptoms syndrome; BS, basic symptom criteria; PANSS, Positive and Negative Syndrome Scale; HAMD, Hamilton Depression Scale.

Bolded p values <0.05.

Supplementary material

For supplementary material accompanying this paper visit <http://dx.doi.org/10.1017/S0033291715002627>.

Acknowledgements

This work was supported by the Zürich Impulse Program for the Sustainable Development of Mental Health Services (<http://www.zinep.ch>). Beyond funding, this foundation had no further role in the experimental design; collection, analysis, and interpretation of data; the writing of this report; or the decision to submit this paper for publication.

Declaration of Interest

Dr Correll has been a consultant and/or advisor to or has received honoraria from: Actavia, AbbVie, Alkermes, Bristol-Myers Squibb, Eli Lilly, Genentech, Gerson Lehrman Group, IntraCellular Therapies, Janssen/J&J, Lundbeck, MedAvante, Medscape, Otsuka, Pfizer, ProPhase, Reviva, Roche, Sunovion, Supernus, and Takeda. He has received grant support from BMS, Otsuka, and Takeda. Dr Walitza has received lecture honoraria from AstraZeneca, Eli Lilly, and Janssen Cilag in the last five years. Dr Rössler has served as a consultant or received honoraria from Eli Lilly Suisse, Janssen-Cilag, Interpharma, FOMF, Med-Update, SVA Sozialversicherungsanstalt Schweiz, I3G, and IVP Networks during the last 5 years.

Drs Gerstenberg, Theodoridou, Frascini, Wotruba, Metzler, Müller, Dvorsky, Heekeren and Ms. Traber-Walker have no conflicts of interest to report.

References

- Addington J, Cadenhead KS, Cannon TD, Cornblatt B, McGlashan TH, Perkins DO, Seidman LJ, Tsuang M, Walker EF, Woods SW, Heinsen R (2007). North American Prodrome Longitudinal Study: a collaborative multisite approach to prodromal schizophrenia research. *Schizophrenia Bulletin* **33**, 665–672.
- Addington J, Heinsen R (2012). Prediction and prevention of psychosis in youth at clinical high risk. *Annual Review of Clinical Psychology* **8**, 269–289.
- APA (2013). *Diagnostic and Statistical Manual of Mental Disorders*, 5th edn. American Psychiatric Association: Arlington, VA.
- Angst J, Adolfsson R, Benazzi F, Gamma A, Hantouche E, Meyer TD, Skeppar P, Vieta E, Scott J (2005). The HCL-32: towards a self-assessment tool for hypomanic symptoms in outpatients. *Journal of Affective Disorders* **88**, 217–233.
- Arango C (2011). Attenuated psychotic symptoms syndrome: how it may affect child and adolescent psychiatry. *European Child & Adolescent Psychiatry* **20**, 67–70.
- Beck AT, Epstein N, Brown G, Steer RA (1988). An inventory for measuring clinical anxiety: psychometric properties. *Journal of Consulting and Clinical Psychology* **56**, 893–897.
- Corcoran C, First M, Cornblatt B (2010). The psychosis risk syndrome and its proposed inclusion in the DSM-V: a risk-benefit analysis. *Schizophrenia Research* **120**, 16–22.
- Correll CU, Hauser M, Auther AM, Cornblatt BA (2010). Research in people with psychosis risk syndrome: a review of the current evidence and future directions. *Journal of*

- Child Psychology and Psychiatry, and Allied Disciplines* **51**, 390–431.
- Dunn LM, Dunn LM, Bulheller S, Häcker H** (1965). *Peabody Picture Vocabulary Test*. American Guidance Service: Circle Pines, MN.
- Fusar-Poli P, Bonoldi I, Yung AR, Borgwardt S, Kempton MJ, Valmaggia L, Barale F, Caverzasi E, McGuire P** (2012). Predicting psychosis. *Archives of General Psychiatry* **69**, 220–229.
- Fusar-Poli P, Borgwardt S, Bechdolf A, Addington J, Riecher-Rössler A, Schultze-Lutter F, Keshavan M, Wood S, Ruhrmann S, Seidman LJ, Valmaggia L, Cannon T, Velthorst E, De Haan L, Cornblatt B, Bonoldi I, Birchwood M, McGlashan T, Carpenter W, McGorry P, Klosterkötter J, McGuire P, Yung A** (2013). The psychosis high-risk state: a comprehensive state-of-the-art review. *JAMA Psychiatry* **70**, 107–120.
- Gaudiano BA, Zimmerman M** (2013). Prevalence of attenuated psychotic symptoms and their relationship with DSM-IV diagnoses in a general psychiatric outpatient clinic. *Journal of Clinical Psychiatry* **74**, 149–155.
- Gerstenberg M, Hauser M, Al-Jadiri A, Sheridan EM, Kishimoto T, Borenstein Y, Vernal DL, David L, Saito E, Landers SE, Carella M, Singh S, Carbon M, Jiménez-Fernández S, Birnbaum ML, Auther A, Carrión RE, Cornblatt BA, Kane JM, Walitza S, Correll CU** (2015). Frequency and correlates of DSM-5 attenuated psychosis syndrome in a sample of adolescent inpatients with non-psychotic psychiatric disorders. *Journal of Clinical Psychiatry* **76**, e1449–e1458.
- Guy W** (1976). *Clinical Global Impression Scale. The ECDEU Assessment Manual for Psychopharmacology-Revised*. US Department of Health, Education, and Welfare Public Health Service Alcohol, Drug Abuse, and Mental Health Administration, DHEW Publication: Rockville, MD, pp. 218–222.
- Hall RC** (1995). Global assessment of functioning. A modified scale. *Psychosomatics* **36**, 267–275.
- Hamilton M** (1960). A rating scale for depression. *Journal of Neurology, Neurosurgery, and Psychiatry* **23**, 56–63.
- Kay S, Fiszbein A, Opler L** (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. *Schizophrenia Bulletin* **13**, 261–276.
- Kelleher I, Corcoran P, Keeley H, Wigman JTW, Devlin N, Ramsay H, Wasserman C, Carli V, Sarchiapone M, Hoven C, Wasserman D, Cannon M** (2013). Psychotic symptoms and population risk for suicide attempt: a prospective cohort study. *JAMA Psychiatry* **140**, 1–9.
- Kelleher I, Murtagh A, Molloy C, Roddy S, Clarke MC, Harley M, Cannon M** (2012). Identification and characterization of prodromal risk syndromes in young adolescents in the community: a population-based clinical interview study. *Schizophrenia Bulletin* **38**, 239–246.
- Klosterkötter J, Ruhrmann S, Schultze-Lutter F, Salokangas RKR, Linszen D, Birchwood M, Juckel G, Morrison A, Vázquez-Barquero JL, Hambrecht M, VON Reventlow H** (2005). The European Prediction of Psychosis Study (EPOS): integrating early recognition and intervention in Europe. *World Psychiatry* **4**, 161–167.
- Lecrubier Y, Sheehan D, Weiller E, Amorim P, Bonora I, Harnett Sheehan K, Janavs J, Dunbar G** (1997). The Mini International Neuropsychiatric Interview (MINI). A short diagnostic structured interview: reliability and validity according to the CIDI. *European Psychiatry* **12**, 224–231.
- Lehrl S, Triebig G and Fischer B** (1995). Multiple choice vocabulary test MWT as a valid and short test to estimate premorbid intelligence. *Acta Neurologica Scandinavica* **91**, 335–345.
- Lindgren M, Manninen M, Kalska H, Mustonen U, Laajasalo T, Moilanen K, Huttunen M, Cannon TD, Suvisaari J, Therman S** (2014). Predicting psychosis in a general adolescent psychiatric sample. *Schizophrenia Research* **158**, 1–6.
- McGlashan T, Walsh B, Woods S** (2010). *The Psychosis-Risk Syndrome. Handbook for Diagnosis and Follow-Up*. Oxford University Press: New York, NY.
- Metzler S, Dvorsky D, Wyss C, Müller M, Traber-Walker N, Walitza S, Theodoridou A, Rössler W, Heekeren K** (2014). Neurocognitive profiles in help-seeking individuals: comparison of risk for psychosis and bipolar disorder criteria. *Psychological Medicine* **44**, 3543–3555.
- Ruhrmann S, Schultze-Lutter F, Salokangas RKR, Heinimaa M, Linszen D, Dingemans P, Birchwood M, Patterson P, Juckel G, Heinz A, Morrison A, Lewis S, von Reventlow HG, Klosterkötter J, Article O** (2010). Prediction of psychosis in adolescents and young adults at high risk. *Archives of General Psychiatry* **67**, 241–251.
- Schimmelmann B, Walger P, Schultze-Lutter F** (2013). The significance of at-risk symptoms for psychosis in children and adolescents. *Canadian Journal of Psychiatry* **58**, 32–40.
- Schimmelmann BG, Schultze-Lutter F** (2012). Early detection and intervention of psychosis in children and adolescents: urgent need for studies. *European Child & Adolescent Psychiatry* **21**, 239–241.
- Schultze-Lutter F** (2007). Predicting first-episode psychosis by basic symptom criteria. *Clinical Neuropsychiatry* **4**, 11–22.
- Schultze-Lutter F, Klosterkötter J, Ruhrmann S** (2014). Improving the clinical prediction of psychosis by combining ultra-high risk criteria and cognitive basic symptoms. *Schizophrenia Research* **154**, 100–106.
- Schultze-Lutter F, Koch E** (2010). *Schizophrenia Proneness Instrument, Child & Youth Version (SPI-CY)*. Giovanni Fioriti Editore s.r.l.: Roma.
- Schultze-Lutter F, Michel C, Ruhrmann S, Schimmelmann BG** (2013). Prevalence and clinical significance of DSM-5-attenuated psychosis syndrome in adolescents and young adults in the general population: the Bern Epidemiological At-Risk (BEAR) Study. *Schizophrenia Bulletin* **40**, 1499–1508.
- Schultze-Lutter F, Michel C, Schmidt SJ, Schimmelmann BG, Maric NP, Salokangas RKR, Riecher-Rössler A, van der Gaag M, Nordentoft M, Raballo A, Meneghelli A, Marshall M, Morrison A, Ruhrmann S, Klosterkötter J** (2015). EPA guidance on the early detection of clinical high risk states of psychoses. *European Psychiatry* **30**, 405–416.
- Sheehan DV, Sheehan KH, Shytle RD, Janavs J, Bannon Y, Rogers JE, Milo KM, Stock SL, Wilkinson B** (2010). Reliability and validity of the Mini International Neuropsychiatric Interview for Children and Adolescents (MINI-KID). *Journal of Clinical Psychiatry* **71**, 313–326.

- Theodoridou A, Heekeren K, Dvorsky D, Metzler S, Franscini M, Haker H, Kawohl W, Rüschi N, Walitza S, Rössler W** (2014). Early recognition of high risk of bipolar disorder and psychosis: an overview of the ZInEP 'Early Recognition' Study. *Frontiers in Public Health* **2**, 166.
- Welsh P, Tiffin PA** (2012). Experience of child and adolescent mental health clinicians working within an at-risk mental state for psychosis service: a qualitative study. *Early Intervention in Psychiatry* **6**, 207–211.
- Welsh P, Tiffin PA** (2014). The 'At-Risk Mental State' for psychosis in adolescents: clinical presentation, transition and remission. *Child Psychiatry and Human Development* **45**, 90–98.
- Woods SW, Addington J, Bearden CE, Cadenhead KS, Cannon TD, Cornblatt BA, Mathalon DH, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, McGlashan TH** (2013). Psychotropic medication use in youth at high risk for psychosis: comparison of baseline data from two research cohorts 1998–2005 and 2008–2011. *Schizophrenia Research* **148**, 99–104.
- Yang LH, Wonpat-Borja AJ, Opler MG, Corcoran CM** (2010). Potential stigma associated with inclusion of the psychosis risk syndrome in the DSM-V: an empirical question. *Schizophrenia Research* **120**, 42–48.
- Yung AR, Woods SW, Ruhrmann S, Addington J, Schultze-Lutter F, Cornblatt BA, Amminger GP, Bechdolf A, Birchwood M, Borgwardt S, Cannon TD, de Haan L, French P, Fusar-Poli P, Keshavan M, Klosterkötter J, Kwon JS, McGorry PD, McGuire P, Mizuno M, Morrison AP, Riecher-Rössler A, Salokangas RKR, Seidman LJ, Suzuki M, Valmaggia L, van der Gaag M, Wood SJ, McGlashan TH** (2012). Whither the attenuated psychosis syndrome? *Schizophrenia Bulletin* **38**, 1130–1134.
- Ziermans TB, Schothorst PF, Sprong M, van Engeland H** (2011). Transition and remission in adolescents at ultra-high risk for psychosis. *Schizophrenia Research* **126**, 58–64.